Treatment of resistant visceral leishmaniasis with interferon gamma in combination with liposomal amphotericin B and allopurinol

This report describes the first case of visceral leishmaniasis (VL) resistant to pentavalent antimonials and also the first use of combinational therapy in Iran. The patient was a two-year old boy, from a non-endemic area for leishmaniasis in northern Iran, presenting with pentavalent antimonial res...

Full description

Saved in:
Bibliographic Details
Published in:Parasitology international 2019-10, Vol.72, p.101934-101934, Article 101934
Main Authors: Khodabandeh, Mahmoud, Rostami, Ali, Borhani, Katayoun, Gamble, H. Ray, Mohammadi, Mohsen
Format: Article
Language:English
Subjects:
Amphotericin B
Interferon gamma
Iran
Resistant
Visceral leishmaniasis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c362t-acd47e73b7ebdf3545aa0a330290aca7c756494a28a0a9ca23680b40335f1ab3
cites cdi_FETCH-LOGICAL-c362t-acd47e73b7ebdf3545aa0a330290aca7c756494a28a0a9ca23680b40335f1ab3
container_end_page 101934
container_issue
container_start_page 101934
container_title Parasitology international
container_volume 72
creator Khodabandeh, Mahmoud
Rostami, Ali
Borhani, Katayoun
Gamble, H. Ray
Mohammadi, Mohsen
description This report describes the first case of visceral leishmaniasis (VL) resistant to pentavalent antimonials and also the first use of combinational therapy in Iran. The patient was a two-year old boy, from a non-endemic area for leishmaniasis in northern Iran, presenting with pentavalent antimonial resistant VL. Additional treatment with conventional and liposomal amphotericin B was not effective. A complete cure was achieved following a three week treatment with liposomal amphotericin B (5 mg/kg/day for 5 days, then on the 14th and 21st days), allopurinol (25 mg/day for 5 days, then on the 14th and 21st days) and interferon gamma (50 μg/m2 subcutaneously three times weekly). Our results suggest a need for further studies to identify resistant Leishmania species and their susceptibility to different treatment regimens.
doi_str_mv 10.1016/j.parint.2019.101934
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2232124616</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1383576918300084</els_id><sourcerecordid>2232124616</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-acd47e73b7ebdf3545aa0a330290aca7c756494a28a0a9ca23680b40335f1ab3</originalsourceid><addsrcrecordid>eNp9kE1v1DAQhi1URD_gHyDkI5cs_kji9QWJVtBWqsRl79bEmbBe2XGwvUXc-Ol4ScuxJ9uvn5l35iXkPWcbznj_6bBZILm5bATj-iRp2b4iF3yrZMOk0Gf1Lrey6VSvz8llzgfGeKcUf0POJedCc60uyJ9dQigB50LjRBNmlwvUx6PLFhN46tHlfYDZQf2iv1zZ02qKacIUZ_oDQoAqUBvD4GYoror_IO-WmGOoHSAs-1grnK3cNYV5pOB9XI51-ujfktcT-Izvns4rsvv2dXdz1zx8v72_-fLQWNmL0oAdW4VKDgqHcZJd2wEwkJIJzcCCsqrrW92C2FZZWxCy37KhZVJ2E4dBXpGPa9slxZ9HzMWE04bew4zxmI0QUnDR9ryvaLuiNsWcE05mSS5A-m04M6fozcGs0ZtT9GaNvpZ9eHI4DgHH_0XPWVfg8wpgXfPRYTLZOpwtji6hLWaM7mWHv2gNmk8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2232124616</pqid></control><display><type>article</type><title>Treatment of resistant visceral leishmaniasis with interferon gamma in combination with liposomal amphotericin B and allopurinol</title><source>Elsevier</source><creator>Khodabandeh, Mahmoud ; Rostami, Ali ; Borhani, Katayoun ; Gamble, H. Ray ; Mohammadi, Mohsen</creator><creatorcontrib>Khodabandeh, Mahmoud ; Rostami, Ali ; Borhani, Katayoun ; Gamble, H. Ray ; Mohammadi, Mohsen</creatorcontrib><description>This report describes the first case of visceral leishmaniasis (VL) resistant to pentavalent antimonials and also the first use of combinational therapy in Iran. The patient was a two-year old boy, from a non-endemic area for leishmaniasis in northern Iran, presenting with pentavalent antimonial resistant VL. Additional treatment with conventional and liposomal amphotericin B was not effective. A complete cure was achieved following a three week treatment with liposomal amphotericin B (5 mg/kg/day for 5 days, then on the 14th and 21st days), allopurinol (25 mg/day for 5 days, then on the 14th and 21st days) and interferon gamma (50 μg/m2 subcutaneously three times weekly). Our results suggest a need for further studies to identify resistant Leishmania species and their susceptibility to different treatment regimens.</description><identifier>ISSN: 1383-5769</identifier><identifier>EISSN: 1873-0329</identifier><identifier>DOI: 10.1016/j.parint.2019.101934</identifier><identifier>PMID: 31129197</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Amphotericin B ; Interferon gamma ; Iran ; Resistant ; Visceral leishmaniasis</subject><ispartof>Parasitology international, 2019-10, Vol.72, p.101934-101934, Article 101934</ispartof><rights>2019 Elsevier B.V.</rights><rights>Copyright © 2019 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-acd47e73b7ebdf3545aa0a330290aca7c756494a28a0a9ca23680b40335f1ab3</citedby><cites>FETCH-LOGICAL-c362t-acd47e73b7ebdf3545aa0a330290aca7c756494a28a0a9ca23680b40335f1ab3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31129197$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Khodabandeh, Mahmoud</creatorcontrib><creatorcontrib>Rostami, Ali</creatorcontrib><creatorcontrib>Borhani, Katayoun</creatorcontrib><creatorcontrib>Gamble, H. Ray</creatorcontrib><creatorcontrib>Mohammadi, Mohsen</creatorcontrib><title>Treatment of resistant visceral leishmaniasis with interferon gamma in combination with liposomal amphotericin B and allopurinol</title><title>Parasitology international</title><addtitle>Parasitol Int</addtitle><description>This report describes the first case of visceral leishmaniasis (VL) resistant to pentavalent antimonials and also the first use of combinational therapy in Iran. The patient was a two-year old boy, from a non-endemic area for leishmaniasis in northern Iran, presenting with pentavalent antimonial resistant VL. Additional treatment with conventional and liposomal amphotericin B was not effective. A complete cure was achieved following a three week treatment with liposomal amphotericin B (5 mg/kg/day for 5 days, then on the 14th and 21st days), allopurinol (25 mg/day for 5 days, then on the 14th and 21st days) and interferon gamma (50 μg/m2 subcutaneously three times weekly). Our results suggest a need for further studies to identify resistant Leishmania species and their susceptibility to different treatment regimens.</description><subject>Amphotericin B</subject><subject>Interferon gamma</subject><subject>Iran</subject><subject>Resistant</subject><subject>Visceral leishmaniasis</subject><issn>1383-5769</issn><issn>1873-0329</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kE1v1DAQhi1URD_gHyDkI5cs_kji9QWJVtBWqsRl79bEmbBe2XGwvUXc-Ol4ScuxJ9uvn5l35iXkPWcbznj_6bBZILm5bATj-iRp2b4iF3yrZMOk0Gf1Lrey6VSvz8llzgfGeKcUf0POJedCc60uyJ9dQigB50LjRBNmlwvUx6PLFhN46tHlfYDZQf2iv1zZ02qKacIUZ_oDQoAqUBvD4GYoror_IO-WmGOoHSAs-1grnK3cNYV5pOB9XI51-ujfktcT-Izvns4rsvv2dXdz1zx8v72_-fLQWNmL0oAdW4VKDgqHcZJd2wEwkJIJzcCCsqrrW92C2FZZWxCy37KhZVJ2E4dBXpGPa9slxZ9HzMWE04bew4zxmI0QUnDR9ryvaLuiNsWcE05mSS5A-m04M6fozcGs0ZtT9GaNvpZ9eHI4DgHH_0XPWVfg8wpgXfPRYTLZOpwtji6hLWaM7mWHv2gNmk8</recordid><startdate>20191001</startdate><enddate>20191001</enddate><creator>Khodabandeh, Mahmoud</creator><creator>Rostami, Ali</creator><creator>Borhani, Katayoun</creator><creator>Gamble, H. Ray</creator><creator>Mohammadi, Mohsen</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20191001</creationdate><title>Treatment of resistant visceral leishmaniasis with interferon gamma in combination with liposomal amphotericin B and allopurinol</title><author>Khodabandeh, Mahmoud ; Rostami, Ali ; Borhani, Katayoun ; Gamble, H. Ray ; Mohammadi, Mohsen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-acd47e73b7ebdf3545aa0a330290aca7c756494a28a0a9ca23680b40335f1ab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Amphotericin B</topic><topic>Interferon gamma</topic><topic>Iran</topic><topic>Resistant</topic><topic>Visceral leishmaniasis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khodabandeh, Mahmoud</creatorcontrib><creatorcontrib>Rostami, Ali</creatorcontrib><creatorcontrib>Borhani, Katayoun</creatorcontrib><creatorcontrib>Gamble, H. Ray</creatorcontrib><creatorcontrib>Mohammadi, Mohsen</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Parasitology international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khodabandeh, Mahmoud</au><au>Rostami, Ali</au><au>Borhani, Katayoun</au><au>Gamble, H. Ray</au><au>Mohammadi, Mohsen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of resistant visceral leishmaniasis with interferon gamma in combination with liposomal amphotericin B and allopurinol</atitle><jtitle>Parasitology international</jtitle><addtitle>Parasitol Int</addtitle><date>2019-10-01</date><risdate>2019</risdate><volume>72</volume><spage>101934</spage><epage>101934</epage><pages>101934-101934</pages><artnum>101934</artnum><issn>1383-5769</issn><eissn>1873-0329</eissn><abstract>This report describes the first case of visceral leishmaniasis (VL) resistant to pentavalent antimonials and also the first use of combinational therapy in Iran. The patient was a two-year old boy, from a non-endemic area for leishmaniasis in northern Iran, presenting with pentavalent antimonial resistant VL. Additional treatment with conventional and liposomal amphotericin B was not effective. A complete cure was achieved following a three week treatment with liposomal amphotericin B (5 mg/kg/day for 5 days, then on the 14th and 21st days), allopurinol (25 mg/day for 5 days, then on the 14th and 21st days) and interferon gamma (50 μg/m2 subcutaneously three times weekly). Our results suggest a need for further studies to identify resistant Leishmania species and their susceptibility to different treatment regimens.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>31129197</pmid><doi>10.1016/j.parint.2019.101934</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1383-5769
ispartof Parasitology international, 2019-10, Vol.72, p.101934-101934, Article 101934
issn 1383-5769
1873-0329
language eng
recordid cdi_proquest_miscellaneous_2232124616
source Elsevier
subjects Amphotericin B
Interferon gamma
Iran
Resistant
Visceral leishmaniasis
title Treatment of resistant visceral leishmaniasis with interferon gamma in combination with liposomal amphotericin B and allopurinol
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T16%3A33%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20resistant%20visceral%20leishmaniasis%20with%20interferon%20gamma%20in%20combination%20with%20liposomal%20amphotericin%20B%20and%20allopurinol&rft.jtitle=Parasitology%20international&rft.au=Khodabandeh,%20Mahmoud&rft.date=2019-10-01&rft.volume=72&rft.spage=101934&rft.epage=101934&rft.pages=101934-101934&rft.artnum=101934&rft.issn=1383-5769&rft.eissn=1873-0329&rft_id=info:doi/10.1016/j.parint.2019.101934&rft_dat=%3Cproquest_cross%3E2232124616%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c362t-acd47e73b7ebdf3545aa0a330290aca7c756494a28a0a9ca23680b40335f1ab3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2232124616&rft_id=info:pmid/31129197&rfr_iscdi=true